The Biomedical Informatics Core was established in 1998 to meet the information management needs of Cancer Center investigators. The Core provides a broad range of hardware, software and personnel resources that serve many investigators and several other shared resource facilities. The Core also works in collaboration with City of Hope and Cancer Center governance committees to promulgate standards, optimize systems and minimize redundancy through continued integration of data, databases, applications and processes. Over the last five years, BIC has become the most widely used Cancer Center shared resource, and Core usage continues to increase each year. A new subscription-based chargeback policy was implemented in October 2003, and chargeback revenue has increased from $7,250 in 2003 to $66,700 in 2006. Since the last competitive renewal, over 1/4 (276/1001) of all Cancer Center peer-reviewed publications involved the use of informatics shared resources. Throughout this evaluation period, the Core has significantly expanded the depth, breadth and cost-effectiveness of support for Center research. Examples include (1) new Citrix-based software deployment technologies that replace hundreds of software installations on individual workstations and provide secure, platform-independent, remote access to Core resourcess via the Internet and City of Hope intranet;(2) a new research and technology collaboration with the San Diego Supercomputing Center to pursue joint funding opportunities and host the Core's most computationally-intensive bioinformatics applications on the TeraGrid national supercomputing network;(3) development and delivery of more than 20 end-user training programs in collaboration with commercial software vendors and the National Center for Biotechnology Information (NCBI);and (4) funded participation in the caBIG Clinical Trials Management Systems (CTMS) workspace to develop workflows, information models and open-source software applications to facilitate Adverse Event (AE) reporting on a national scale. During FY 2006, the Core provided informatics support for 135 Cancer Center members;76% of the users supported by biomedical informatics had peer-reviewed funding. Annual budget for the core is $2,065,231 (44% institutional, 3% user fees, 45% other), with 7% ($151,000) requested from the CCSG.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications